Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8726
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors ; day:1 ; month:3 ; year:2021 ; pages:1-9
World journal of urology ; (1.3.2021), 1-9
- Creator
-
Janisch, Florian
Klotzbücher, Thomas
Marks, Phillip
Kienapfel, Christina
Meyer, Christian P.
Yu, Hang
Fühner, Constantin
Hillemacher, Tobias
Mori, Keiichiro
Mostafei, Hadi
Shariat, Shahrokh F.
Fisch, Margit
Dahlem, Roland
Rink, Michael
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00345-021-03628-2
- URN
-
urn:nbn:de:101:1-2021041523482963525423
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Janisch, Florian
- Klotzbücher, Thomas
- Marks, Phillip
- Kienapfel, Christina
- Meyer, Christian P.
- Yu, Hang
- Fühner, Constantin
- Hillemacher, Tobias
- Mori, Keiichiro
- Mostafei, Hadi
- Shariat, Shahrokh F.
- Fisch, Margit
- Dahlem, Roland
- Rink, Michael
- SpringerLink (Online service)
Other Objects (12)
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells
Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
Editorial: Targeting bruton tyrosine kinase
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course